Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor

Vaccine

Volumn 32, Issue 8, 2014, Pages 1003-1011

  Tapia, Felipe ^a,b   Vogel, Thomas ^a,c   Genzel, Yvonne ^a   Behrendt, Ilona ^a   Hirschel, Mark ^d   Gangemi, J David ^d   Reichl, Udo ^a,e  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c ESSLINGEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

^d Biovest International Inc   (United States)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Adherent cells; Hollow fiber bioreactor; Influenza; MDCK; MDCK.SUS2; Suspension cells

Indexed keywords

ADHERENT CELL; ARTICLE; CAPILLARY TUBE; CELL COUNT; CELL CULTURE; CELL SUSPENSION; CONTROLLED STUDY; GLUCOSE TRANSPORT; HOLLOW FIBER REACTOR; INFLUENZA VIRUS A; MDCK CELL; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS STRAIN; VIRUS TITRATION;

ADHERENT CELLS; HOLLOW FIBER BIOREACTOR; INFLUENZA; MDCK; MDCK.SUS2; SUSPENSION CELLS;

ANIMALS; BIOREACTORS; DOGS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; VIRUS CULTIVATION;

EID: 84893024244     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.044     Document Type: Article

References (43)

1. Genzel Y., Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 2009, 8:1681-1692.
2. Sun B., Yu X., Kong W., Sun S., Yang P., Zhu C., et al. Production of influenza H1N1 vaccine from MDCK cells using a novel disposable packed-bed bioreactor. Appl Microbiol Biotechnol 2013, 97:1063-1070.
3. Wood J.M., Oxford J.S., Dunleavy U., Newman R.W., Major D., Robertson J.S., et al. Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 1989, 171(July (1)):214-221.
4. Katz J.M., Webster R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989, 160(August (2)):191-198.
5. Frey S., Vesikari T., Szymczakiewicz-Multanowska A., Lattanzi M., Izu A., Groth N., et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51(9):997-1004.
6. Tree J.A., Richardson C., Fooks A.R., Clegg J.C., Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 2001, 19(25-26):3444-3450.
7. Gregersen J.P., Schmitt H.J., Trusheim H., Bröker M. Safety of MDCK cell culture-based influenza vaccines. Future Microbiol 2011, 6(2):143-152.
8. Le Ru A., Jacob D., Transfiguracion J., Ansorge S., Henry O., Kamen A.A. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 2010, 28(May (21)):3661-3671.
9. Chu L., Robinson D.K. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001, 12(2):180-187.
10. Hu W.S., Aunins J.G. Large-scale mammalian cell culture. Curr Opin Biotechnol 1997, 8(2):148-153.
11. Bock A., Schulze-Horsel J., Schwarzer J., Rapp E., Genzel Y., Reich U. High-density microcarrier cell cultures for influenza virus production. Biotechnol Prog 2011, 27(January (1)):241-250.
12. Petiot E., Jacob D., Lanthier S., Lohr V., Ansorge S., Kamen A.A. Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol 2011, 11(Sept 1):84.
13. Wong K.T.K., Peter C.H., Greenfield P.F., Reid S., Nielsen L.K. Low multiplicity infection of insect cells with a recombinant baculovirus: the cell yield concept. Biotechnol Bioeng 1996, 49:659-666.
14. Lindsay D.A., Betenbaugh M.J. Quantification of cell-culture factors affecting recombinant protein yields in baculovirus-infected insect cells. Biotechnol Bioeng 1992, 39:614-618.
15. Kuczewski M., Schirmer E., Lain B., Zarbis-Papastoitsis G. A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnol J 2011, 6(1):56-65.
16. Crowley J, Wuebben M, Coco Martin JM, inventors. Process for cell culturing by continuous perfusion and alternating tangential flow patent WO2005095578 (A1); 2005.
17. Henry O., Dormond E., Perrier M., Karmen A. Insights into adhenoviral vector production kinetics in acoustic filter-based perfusion cultures. Biotechnol Bioeng 2004, 86:765-774.
18. Woodside S.M., Bowen B.D., Piret J.M. Mammalian cell retention devices for stirred perfusion bioreactors. Cytotechnology 1999, 28:163-175.
19. Hirschel M., Gangemi J.D., McSharry J., Myers C. Novel uses for hollow fiber bioreactors. Genet Eng Biotechnol News 2011, 31(12):42-44.
20. Knazek R., Gullino P., Kohler P., Dedrik R. Cell culture on artificial capillaties: an approach to tissue growth in vitro. Science 1972, 178:65-67.
21. Piret J.M., Cooney C.L. Mammalian cell and protein distributions in ultrafiltration hollow fiber bioreactors. Biotechnol Bioeng 1990, 36(9):902-910.
22. Langer R., Vacanti J. Tissue engineering. Science 1993, 260:920-926.
23. Kessler N., Thomas G., Gerentes L., Delfosse G., Aymard M. Hybridoma growth in a new generation hollow fibre bioreactor: antibody productivity and consistency. Cytotechnology 1997, 24:109-119.
24. Chresand T., Gillies R., Dale B. Optimum fiber spacing in a hollow fiber bioreactor. Biotechnol Bioeng 1988, 32:983-992.
25. Piret J., Cooney C. Immobilized mammalian cell cultivation in hollow fiber bioreactors. Biotechnol Adv 1990, 8(4):763-783.
26. McSharry J.J., Drusano G.L. Antiviral pharmacodynamics in hollow fibre bioreactors. Antivir Chem Chemother 2011, 21(5):183-192.
27. Lohr V., Genzel Y., Behrendt I., Scharfenberg K., Reichl U. A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 2010, 28(38):6256-6264.
28. Kalbfuss Knöchlein A., Kröber T., Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 2008, 36:145-161.
29. Genzel Y., Reichl U. Vaccine production-state of the art and future needs in upstream processing. Animal cell biotechnology: methods and protocols 2007, 457-473. Humana Press Inc. R. Poertner (Ed.).
30. Rodrigues M.T.A., Vilaça P.R., Garbuio A., Takagi M., Barbosa S., Léo P., et al. Glucose uptake rate as a tool to estimate hybridoma growth in a packed bed bioreactor. Bioprocess Eng 1999, 21(6):543-546.
31. Lee J.C., Kim D.Y., Oh D.J., Chang H.N. Long-term operation of depth filter perfusion systems (DFPS) for monoclonal antibody production using recombinant CHO cells: effect of temperature, pH, and dissolved oxygen. Biotechnol Bioprocess Eng 2008, 13(4):401-409.
32. Wahl A., Sidorenko Y., Dauner M., Genzel Y., Reichl U. Metabolic flux model for an anchorage-dependent MDCK cell line: characteristic growth phases and minimum substrate consumption flux distribution. Biotechnol Bioeng 2008, 101(1):135-152.
33. ® Bioreactor microcarrier culture in 1-10L scale. Vaccine 2007, 25(20):3987-3995.
34. Genzel Y, Vogel T, Buck J, Behrendt I, Vazquez Ramirez D, Schiedner G, et al. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells, Vaccine [in press].
35. Frensing T., Heldt F.S., Pflugmacher A., Behrendt I., Jordan I., Flockerzi D., et al. Continuous virus production in cell culture shows a periodic accumulation of defective interfering particles. PLoS ONE 2013, 8(9):e72288.
36. Paillet C., Forno G., Soldano N., Kratje R., Echeverrigaray M. Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero). Vaccine 2011, 29:7212-7217.
37. Genzel Y., Olmer R.M., Schäfer B., Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 2006, 24(35-36):6074-6087.
38. Genzel Y., Behrendt I., Rödig J., Rapp E., Kueppers C., Kochanek S., et al. CAP, a new human suspension cell line for influenza virus production. Appl Microbiol Biotechnol 2012, [Epub ahead of print].
39. Genzel Y., Dietzsch C., Rapp E., Schwarzer J., Reichl U. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl Microbiol Biotechnol 2010, 88:461-475.
40. Wolf M.W., Reichl U. Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 2011, 10(10):1451-1475.
41. George M., Farooq M., Dang T., Cortes B., Liu J., Maranga L. Production of cell culture (MDCK) live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol Bioeng 2010, 106(6):906-917.
42. Isken B., Genzel Y., Reichl U. Productivity, apoptosis, and infection dynamics of influenza A/PR/8 strains and A/PR/8-based reassortants. Vaccine 2012, 30(35):5253-5261.
43. Peschel B., Frentzel S., Laske T., Genzel Y., Reichl U. Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line. Vaccine 2013, 31(48):5693-5699.